ValiRx plc (LSE:VAL) has expanded the intellectual property portfolio of its majority-owned subsidiary Cytolytix after the European Patent Office indicated its intention to grant a second European patent covering polyleucine-based anti-cancer peptides licensed from King’s College London. The development adds further protection around Cytolytix’s early-stage oncology technology.
The anticipated patent grant complements an existing European patent covering nanoparticle formulations of anti-cancer peptides. Together, the patents broaden the intellectual property surrounding Cytolytix’s therapeutic platform and could strengthen its position when pursuing future licensing agreements, strategic partnerships or external investment.
Cytolytix has also filed a new patent application covering second-generation lipid-based delivery formulations for an oncolytic peptide. The filing is supported by experimental data indicating that the formulations can induce immunogenic cell death in triple negative breast cancer cells, potentially providing an additional mechanism through which the technology could stimulate an anti-tumour immune response.
Management believes the combination of proprietary delivery formulations and immune-activating characteristics could support the development of differentiated oncology products. The technology is being considered for both human and veterinary applications, aligning with ValiRx’s comparative oncology strategy and potentially broadening the commercial opportunities available for the platform.
Strengthening the intellectual property estate could improve Cytolytix’s ability to protect its technology as development progresses while increasing its attractiveness to prospective commercial partners. However, ValiRx’s broader outlook remains constrained by minimal revenue, continuing losses and ongoing cash consumption, which is putting pressure on shareholder equity despite relatively low debt. Technical indicators also remain weak, with the shares below major moving averages and MACD in negative territory, while conventional valuation metrics provide limited support given negative earnings and the absence of a dividend yield.
More about ValiRx plc
ValiRx plc is a UK-based life sciences company focused on early-stage cancer therapeutics and women’s health. The company provides scientific, financial and commercial support to help translate innovative research into potential clinical-stage medicines. Listed on AIM under the ticker VAL, ValiRx develops and incubates drug candidates through pre-clinical stages before seeking to out-license or partner promising assets through its subsidiary companies for further clinical and commercial development.
Leave a Reply